A Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VIS954 in Healthy Adult Participants

Phase 1 Completed 54 enrolled Otsuka Pharmaceutical Development & Commercialization, Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a first-in-human (FIH), randomized, placebo-controlled, double-blind, single ascending dose (SAD) study to assess the safety and tolerability of VIS954, a monoclonal antibody, in healthy adult male and female participants.

Timeline

Start: 2023-11-21
Primary completion: 2024-07-19
Completion: 2024-07-19

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	VIS954	Monoclonal antibody	—	Subcutaneous

Indications

No indication recorded.